Abstract:This study examines outcomes and predictors of treatment failure (TF) following high‐intensity focused ultrasound (HIFU) therapy for localized prostate cancer (PCa). A multinational prospective cohort study was conducted, analysing serial prostate specific antigen (PSA), MRI, biopsies, adverse events and functional outcomes. Results show low incidence of TF, with initial T‐stage and positive biopsy cores predicting TF. Minimal adverse events and positive functional outcomes were observed. The findings highlight HIFU as a promising treatment for low‐to‐intermediate‐risk PCa, though long‐term data are needed to assess oncological outcomes. Background High‐intensity focused ultrasound (HIFU) emerged as a novel approach for the treatment of localized prostate cancer (PCa). However, prospective studies on HIFU‐related outcomes and predictors of treatment failure (TF) remain scarce. Materials and Methods We conducted a multinational prospective cohort study among patients undergoing HIFU therapy for localized, low‐ to intermediate‐risk PCa. Follow‐up data on serial prostate specific antigen (PSA), multi‐parametric magnetic resonance imaging (mpMRI), targeted/systematic biopsies, adverse events and functional outcomes were collected. The primary endpoint was TF, defined as histologically confirmed PCa requiring whole‐gland salvage treatment. Uni‐ and multi‐variable adjusted hazard ratios (HRs) were calculated using Cox proportional hazard regression models. Results At baseline, mean (standard deviation) age was 64.14 (7.19) years, with the majority of patients showing T‐stage 1 (73.9%) and International Society of Urological Pathology grading system Grade 2 (58.8%). PSA nadir (median, 1.70 ng/mL) was reached after 6 months. Of all patients recruited, 16% had clinically significant PCa, as confirmed by biopsy, of which 13.4% had TF. Notably, T‐stage and number of positive cores at initial biopsy were independent predictors of TF during follow‐up (HR [95% CI] 1.27 [1.02–1.59] and 5.02 [1.80–14.03], respectively). Adverse events were minimal (17% and 8% early and late adverse events, respectively), with stable or improved functional outcomes in the majority of patients. Conclusions This interim analysis of a multinational study on HIFU therapy for the management of low‐to‐intermediate‐risk PCa reveals good functional outcomes, minimal adverse events and low incidence of TF over the short‐term. Data on long‐term outcomes, specifically as it relates to oncological outcomes, are awaited eagerly.

Prospective close monitoring of the effect of vascular-targeted photodynamic therapy and high intensity focused ultrasound of localized prostate cancer by multiparametric magnetic resonance imaging

MRI-guided Focused Ultrasound Focal Therapy for Intermediate-Risk Prostate Cancer: Final Results from a 2-year Phase II Clinical Trial

Focal Therapy for Prostate Cancer with In-Bore MR-guided Focused Ultrasound: Two-Year Follow-up of a Phase I Trial-Complications and Functional Outcomes

A Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation

Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer

Comparison of Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) and Prostate Imaging after Focal Ablation (PI-FAB) for Detecting Recurrent Prostate Cancer at Prostate MRI

Imaging predictive biomarkers of response in patients with prostate cancer undergoing high-intensity focused ultrasound (HIFU) focal therapy.

Real-time precision targeted prostate biopsy using transrectal ultrasound-magnetic resonance fusion

T2*-weighted MRI as a non-contrast-enhanced method for assessment of focal laser ablation zone extent in prostate cancer thermotherapy

MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score

Evaluating Diagnostic Accuracy and Inter-reader Agreement of the Prostate Imaging After Focal Ablation Scoring System

In Vivo Small Animal Imaging for Early Assessment of Therapeutic Efficacy of Photodynamic Therapy for Prostate Cancer.

Focal high‐intensity focused ultrasound therapy for localized prostate cancer: An interim analysis of the multinational FASST study

Transperineal laser ablation (TPLA) with ultrasound/MRI fusion guidance in the treatment of localized radiotherapy-resistant prostate cancer

Prostate cancer focal therapy: surgeon experience influences oncological results

Multiparametric MRI and 18 F-PSMA-1007 PET/CT for the Detection of Clinically Significant Prostate Cancer

Biologic Target Volume Delineation and the Application of Three-Dimensional Ultrasound Image System in Hypofractional Radiotherapy for Prostate Cancer.

Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging to Detect Residual Prostate Cancer Following Irreversible Electroporation-A Multicenter Validation Study

Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases

4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study

In vivo assessment of vascular-targeted photodynamic therapy effects on tumor microvasculature using ultrahigh-resolution functional optical coherence tomography